High-risk patient characteristics. Results of the OSCAR Study: epidemiological part

Aim. Program OSCAR-2006 has been initiated with an aim to identify high-risk patients in real-world clinical practice settings. The article presents the results from the epidemiological part of the Program. Material and methods. OSCAR-2006 Study included 235 doctors from 36 Russian cities, and 7098 patients: 3673 males (51,8%), 3425 females (48,2%), aged 25-75 years, with myocardial infarction (MI) and/or myocardial revascularization, and/or stable angina, diabetes mellitus (DM), peripheral artery disease in anamnesis, and, therefore, high cardiovascular risk. Socio-demographic, anthropometric, clinical and some laboratory parameters were assessed. Results. More than 50% of males and 8,8% of females were current smokers. High blood pressure was diagnosed in 83,4%, dyslipidemia – in >70%, DM – in 20% of the patients examined. Therefore, 97,4% of the participants had at least one risk factor. Coronary heart disease (CHD) was diagnosed in almost 80%, mostly in males. Males had MI in anamnesis twice as often as females. By the study start, 6% of the patients had suffered stroke, and 20% had peripheral artery disease. As regards the treatment, 87,2% of the participants received antihypertensive therapy: about 60% - at least 3 antihypertensive medications, 10% - two medications, and only 8,7% were on monotherapy. Conclusion. Studies devoted to clinical practice analysis, problems of high-risk patient identification, adequate prevention and treatment in such individuals should be regarded as an important step towards population-level reduction of cardiovascular risk.

1. Милле Ф., Школьников В.М., Эртриш В., Валлен Ж. Современные тенденции смертности по причинам смертности в России 1965-1994. Москва 1996: 2, 137 с.

2. Sans S, Kesteloot H, Kromhout D. Task force of the European Society of Cardiology on cardiovascular mortality and morbidity statistics in Europe. Eur Heart J 1997; 18(8): 1231-48.

3. Оганов Р.Г., Масленникова Г.Я. Смертность от сердечно-сосудистых и других неинфекционных заболеваний среди трудоспособного населения России. Кардиоваск тер про-фил 2002; 3: 4-8.

4. Медико-демографические показатели Российской Федерации в 2004г. Официальное издание Минздравсоцразвития РФ. Москва 2005.

5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (4S). Lancet 1994; 344: 1383-9.

6. The Cholesterol and Recurrent Events Trail Investigators. The effect of pravastatin on coronary events after myocardial infarction in patientd with average cholesterol levels. N Engl J Med 1998; 335: 1001-9.

7. Athyros VG, Papageorgiou AA, Mercouris BR. The Greak Atorvastatin and acoranary heart disease Evaluation (GREECE) Study. Curr Med Res Opin 2002; 18: 220-8.

8. Serruys PW, de Feuter P, Macaya C, et al., Intervention Prevention Study (LIPID) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trail. JAMA 2002; 287: 3215-2.

9. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.

10. Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/Tex-CAPS Research Group, (1998). Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS. JAMA ; 279: 1615-22.

11. Heart Protection Study Collaborative Group. MRC/BHR Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.

12. Prosper Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trail. Lancet 2002; 360: 1623-30.

13. The ALLHAT Officers and Coordinators for the ALLHAT Collaboration Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.

14. Woolf N. Pathology of atherosclerosis. In: Betterige DJ, Illingworth R, Shepherd J eds. Lipoproteins in health and disease, London: Arnold, 1999.

15. Stamler J, Wenthworth D, Neaton JD, for the MRFIT Research Group. Is the relationship between serujm cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA 1986; 256: 2823-8.

16. Eastern Stroke and coronary heart disease collaborative research group. Blood pressure, cholesterol and stroke in eastern Asia. Lancet 1998; 352: 1801-7.

17. Psaty BM, Anderson M, Kronmal RA, et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. J Am Geriatr Soc 2004; 52: 1639-47.

18. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of tenyear risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.

19. SAS/STAT User’s Guide, Version 6, Forth Edition, Vol.1&2, SAS Institute Inc., Cary, NC, USA, 1990.

20. Чазова Л.В. Многофакторная профилактика ИБС среди населения. Автореф дисс докт мед наук. Москва 1984.

21. Puska P, Nissinen A, Tuomilehto J, et al. The community based strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia Project. Ann Rev Publ Health 1985; 6: 147-93.

22. Kannel WB. Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996; 275: 1571-6.

23. Шальнова С.А., Деев А.Д., Карпов ЮА. Артериальная гипертония и ишемическая болезнь сердца в реальной практике врача кардиолога. Кардиоваск тер профил 2006; 2: 73-80.

24. Давыдова С.С. Прогностическое значение пробы с физической нагрузкой на тредмиле у больных ИБС. Автореф дисс канд мед наук. Москва 2006.

25. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiol 2003; 24: 1601-10.